IRIS
ZAZZI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.499
EU - Europa 13.777
AS - Asia 2.283
AF - Africa 46
SA - Sud America 34
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 12
Totale 32.675
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.443
GB - Regno Unito 4.118
IE - Irlanda 2.554
IT - Italia 1.508
CN - Cina 1.376
SE - Svezia 1.279
UA - Ucraina 1.167
RU - Federazione Russa 1.006
FR - Francia 734
DE - Germania 678
SG - Singapore 487
FI - Finlandia 356
VN - Vietnam 192
ES - Italia 124
BE - Belgio 81
IN - India 55
CA - Canada 44
TR - Turchia 43
CZ - Repubblica Ceca 29
NL - Olanda 24
AU - Australia 20
HK - Hong Kong 20
BR - Brasile 16
CI - Costa d'Avorio 15
JP - Giappone 15
GR - Grecia 14
IR - Iran 14
LU - Lussemburgo 13
EE - Estonia 11
ID - Indonesia 11
AT - Austria 10
EU - Europa 9
DK - Danimarca 8
PL - Polonia 8
SK - Slovacchia (Repubblica Slovacca) 8
ZA - Sudafrica 8
CL - Cile 7
KR - Corea 7
PA - Panama 7
TH - Thailandia 7
UZ - Uzbekistan 7
AR - Argentina 6
BG - Bulgaria 6
RO - Romania 6
AE - Emirati Arabi Uniti 5
KG - Kirghizistan 5
LT - Lituania 5
PH - Filippine 5
CH - Svizzera 4
EG - Egitto 4
HU - Ungheria 4
MW - Malawi 4
MY - Malesia 4
PT - Portogallo 4
TW - Taiwan 4
BW - Botswana 3
BY - Bielorussia 3
IL - Israele 3
LK - Sri Lanka 3
MX - Messico 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
RS - Serbia 3
SA - Arabia Saudita 3
UG - Uganda 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BD - Bangladesh 2
BJ - Benin 2
CY - Cipro 2
EC - Ecuador 2
ET - Etiopia 2
HR - Croazia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
NO - Norvegia 2
SC - Seychelles 2
SS - ???statistics.table.value.countryCode.SS??? 2
A1 - Anonimo 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CO - Colombia 1
GH - Ghana 1
IM - Isola di Man 1
IQ - Iraq 1
JM - Giamaica 1
MA - Marocco 1
ME - Montenegro 1
NC - Nuova Caledonia 1
OM - Oman 1
PE - Perù 1
SI - Slovenia 1
SV - El Salvador 1
ZW - Zimbabwe 1
Totale 32.675
Salva come PNG Salva come JPEG
Città #
Southend 3.754
Fairfield 2.523
Dublin 2.521
Houston 1.637
Chandler 1.527
Ashburn 1.260
Woodbridge 1.132
Jacksonville 972
Seattle 931
Wilmington 927
Ann Arbor 857
Cambridge 854
Siena 604
Princeton 437
Singapore 362
Beijing 326
Nanjing 296
Menlo Park 228
New York 201
Dong Ket 187
San Mateo 183
Boardman 179
Helsinki 160
San Diego 138
Nanchang 112
Málaga 110
Shanghai 104
Munich 97
Dearborn 92
Moscow 85
Rome 79
Brussels 78
London 65
Tianjin 64
Shenyang 55
Hebei 51
Düsseldorf 48
Milan 43
Florence 41
Jiaxing 39
Changsha 36
Kunming 36
Norwalk 36
Bologna 34
Dallas 34
Lancaster 34
Jinan 33
Falls Church 30
San Francisco 29
Fremont 28
Redwood City 28
Toronto 27
Zhengzhou 27
Izmir 26
Los Angeles 26
Hangzhou 24
Ningbo 20
Guangzhou 18
Phoenix 18
Santa Clara 18
Washington 18
Mestre 17
Taizhou 17
Venezia 17
Brno 16
Lappeenranta 16
Abidjan 15
Paris 15
Kilburn 14
Luxembourg 13
Turin 13
Wandsworth 13
Amsterdam 12
Frankfurt am Main 12
Hefei 11
Lanzhou 11
Naples 11
Tallinn 11
Atlanta 10
Chicago 10
Chiswick 10
Edinburgh 10
Fuzhou 10
Padova 10
Tappahannock 10
Ufa 10
Vienna 10
Central 9
Columbus 9
Espoo 9
Leawood 9
Melbourne 9
Brescia 8
Changchun 8
Islington 8
Perugia 8
Prague 8
Roccagorga 8
Stockholm 8
São Paulo 8
Totale 24.372
Salva come PNG Salva come JPEG
Nome #
Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-infected subjects 561
Surrogate markers as a guide to evaluate response to antiretroviral therapy 416
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 338
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 259
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 231
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 217
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 215
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 204
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 200
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 198
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 192
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 185
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 184
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 184
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 182
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 181
Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. 175
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 173
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 171
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 171
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 171
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 169
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 169
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 168
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 164
Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy 164
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 164
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 163
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 159
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 158
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 158
Anticipating policy considerations for a future HIV vaccine: a preliminary study 156
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 155
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 155
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 155
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 154
Neuronal intranuclear inclusion disease: polymerase chain reaction and ultrastructural study of rectal biopsy specimen in a new case 153
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 153
Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type 1 nucleoside reverse transcriptase inhibitors 153
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 152
Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine and protease inhibitors 151
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 151
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 151
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 149
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 149
Antigenicity and immunogenicity of the V3 domain of HIV-1 gp120 expressed on the surface of Streptococcus gordonii. AIDS Res Hum Retroviruses 148
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 147
Detection of genotypically drug-resistant HIV-1 variants and non-B subtypes in recently infected antiretroviral-naive adults in Italy. 147
A child with vestibular neuritis. Is adenovirus implicated? 146
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 146
HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir 146
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 146
A novel methodology for large-scale phylogeny partition 145
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 144
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 144
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 144
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 144
Lack of evidence of HHV-8 DNA in blood cells from heart transplant recipients 143
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 143
Immunoglobulin gene rearrangement analysis in composite Hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells? 143
null 142
FALLIMENTO VIROLOGICO PRECOCE CON SELEZIONE RAPIDA DI FARMACORESISTENZA IN UN PAZIENTE CON HCV GENOTIPO 1, TRATTATO CON PEGINTERFERON, RIBAVIRINA E TELAPREVIR 142
An update to the HIV-TRePS system: The development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype 142
European guidelines on the clinical management of HIV-1 tropism testing 142
HIV-1 and human myelin proteins share an antigenic determinant 141
HIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South America 140
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 140
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database 139
Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment 139
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy 139
Decline of Prevalence of Resistance Associated Substitutions to NS3 and NS5A inhibitors at DAA-failure in Hepatitis C Virus in Italy over the years 2015 to 2018 139
Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. 138
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 137
Phylogenetic analysis provides evidence of interactions between Italian heterosexual and South American homosexual males as the main source of national HIV-1 subtype C epidemics 137
Predicting response to antiretroviral treatment by machine learning: the EuResist project 137
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 136
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 136
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 136
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy 135
Only slight impact of predicted replicative capacity for therapy response prediction 135
Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8 coinfected patients 135
null 135
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 135
Impact of extensive HIV-1 variability on molecular diagnosis in the Congo Basin 134
Nested polymerase chain reaction for detection of human immunodeficiency virus type 1 DNA in clinical specimens. 134
Focal myositis: a polymerase chain reaction analysis for a viral etiology 133
Biotechnology for virus vaccine design, production, and control 133
Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. 133
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 133
Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: analysis from a national drug-resistance database (ARCA) 132
Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression. 132
First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing 131
null 129
The global spread of HIV-1 subtype B epidemic 129
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 128
Concordance between polymerase chain reaction and antibody detection in the diagnosis of human immunodeficiency virus type 1 infection. 128
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 128
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study 128
Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. 128
Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC 127
Totale 16.154
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.582
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.582
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.370 0 0 0 0 597 574 621 800 647 560 192 379
2020/20214.952 228 472 129 433 372 535 417 709 481 412 304 460
2021/20223.917 213 471 270 404 199 148 210 174 301 400 362 765
2022/20235.270 317 517 621 730 510 1.036 148 434 494 159 203 101
2023/20243.752 159 99 318 214 79 1.091 1.286 103 18 63 82 240
2024/20252.079 190 403 841 427 218 0 0 0 0 0 0 0
Totale 33.392